Liquidia (LQDA) Revenue & Revenue Breakdown
Liquidia Revenue Highlights
Latest Revenue (Y)
$17.49M
Latest Revenue (Q)
$4.45M
Main Segment (Y)
Promotion Agreement
Main Geography (Y)
Promotion Agreement
Liquidia Revenue by Period
Liquidia Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | - | 9.75% |
| 2022-12-31 | - | 23.98% |
| 2021-12-31 | - | 1637.81% |
| 2020-12-31 | - | -90.84% |
| 2019-12-31 | - | 198.20% |
| 2018-12-31 | - | -62.70% |
| 2017-12-31 | - | -45.08% |
| 2016-12-31 | - | - |
Liquidia generated $17.49M in revenue during NA 2023, up 9.75% compared to the previous quarter, and up 646.03% compared to the same period a year ago.
Liquidia Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-09-30 | - | 21.56% |
| 2024-06-30 | - | 23.12% |
| 2024-03-31 | - | -34.41% |
| 2023-12-31 | - | 23.19% |
| 2023-09-30 | - | -23.15% |
| 2023-06-30 | - | 6.52% |
| 2023-03-31 | - | -16.18% |
| 2022-12-31 | - | 69.35% |
| 2022-09-30 | - | -19.22% |
| 2022-06-30 | - | 12.20% |
| 2022-03-31 | - | 8.62% |
| 2021-12-31 | - | 1.14% |
| 2021-09-30 | - | -5.85% |
| 2021-06-30 | - | 9.48% |
| 2021-03-31 | - | 316.92% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | -100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | -100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | -100.00% |
| 2018-12-31 | - | 234.89% |
| 2018-09-30 | - | -83.72% |
| 2018-06-30 | - | 12.63% |
| 2018-03-31 | - | -49.01% |
| 2017-12-31 | - | -0.26% |
| 2017-09-30 | - | -8.13% |
| 2017-06-30 | - | 20.91% |
| 2017-03-31 | - | - |
Liquidia generated $4.45M in revenue during Q3 2024, up 21.56% compared to the previous quarter, and up 92.94% compared to the same period a year ago.
Liquidia Revenue Breakdown
Liquidia Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 20 |
|---|---|
| Research and Development Services | - |
| Promotion Agreement | - |
Liquidia's latest annual revenue breakdown by segment (product or service), as of Dec 20: Promotion Agreement (100.00%).
Quarterly Revenue by Product
| Product/Service | Jun 19 | Dec 18 | Sep 18 | Jun 18 |
|---|---|---|---|---|
| Research And Development Services | - | - | - | - |
| Collaboration And Licensing Milestones | - | - | - | - |
| Collaboration And Licensing Non Refundable Upfront Payments | - | - | - | - |
Liquidia's latest quarterly revenue breakdown by segment (product or service), as of Jun 19: Collaboration And Licensing Non Refundable Upfront Payments (83.33%), Collaboration And Licensing Milestones (16.67%), and Research And Development Services (0.00%).
Liquidia Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 20 | Dec 19 | Dec 18 |
|---|---|---|---|
| Promotion Agreement | - | - | - |
| Research and Development Services | - | - | - |
| Non-Refundable Payments - Milestones | - | - | - |
| Non-Refundable Payments - Up-front Payments | - | - | - |
| Collaboration And Licensing Milestones | - | - | - |
| Collaboration And Licensing Non Refundable Upfront Payments | - | - | - |
| Research And Development Services | - | - | - |
Liquidia's latest annual revenue breakdown by geography, as of Dec 20: Promotion Agreement (100.00%).
Quarterly Revenue by Country
| Country | Jun 19 | Dec 18 | Sep 18 | Jun 18 |
|---|---|---|---|---|
| Research And Development Services | - | - | - | - |
| Collaboration And Licensing Milestones | - | - | - | - |
| Collaboration And Licensing Non Refundable Upfront Payments | - | - | - | - |
Liquidia's latest quarterly revenue breakdown by geography, as of Jun 19: Collaboration And Licensing Non Refundable Upfront Payments (83.33%), Collaboration And Licensing Milestones (16.67%), and Research And Development Services (0.00%).
Liquidia Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| BMRN | BioMarin Pharmaceutical | - | - |
| UTHR | United Therapeutics | - | - |
| TECH | Bio-Techne | - | - |
| AMLX | Amylyx Pharmaceuticals | - | - |
| LEGN | Legend Biotech | - | - |
| IMCR | Immunocore | - | - |
| MIRM | Mirum Pharmaceuticals | - | - |
| AGEN | Agenus | - | - |
| LQDA | Liquidia | - | - |
| KRON | Kronos Bio | - | - |
| LYRA | Lyra Therapeutics | - | - |
| GERN | Geron | - | - |
| XFOR | X4 Pharmaceuticals | - | - |
| PCVX | Vaxcyte | - | - |
| GOSS | Gossamer Bio | - | - |
| ABOS | Acumen Pharmaceuticals | - | - |
| INZY | Inozyme Pharma | - | - |
| REPL | Replimune Group | - | - |
| NRXP | NRx Pharmaceuticals | - | - |
| TERN | Terns Pharmaceuticals | - | - |
| LRMR | Larimar Therapeutics | - | - |
| NVCT | Nuvectis Pharma | - | - |
| KALV | KalVista Pharmaceuticals | - | - |